中性粒细胞与淋巴细胞比值:一项评价肝细胞癌患者预后的新指标

王宪波; 高方媛; 刘尧

doi:10.3969/j.issn.1001-5256.2016.04.007

中性粒细胞与淋巴细胞比值:一项评价肝细胞癌患者预后的新指标

DOI: 10.3969/j.issn.1001-5256.2016.04.007

首都医科大学附属北京地坛医院

基金项目:

国家自然基金(81473641,81273743)；重大传染病防治协同创新中心(2011协同创新中心)(PXM2015-014226-000058)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 285
- HTML全文浏览量: 31
- PDF下载量: 277
- 被引次数: 0
出版历程
- 出版日期: 2016-04-20

Neutrophil- lymphocyte ratio: a novel predictor of clinical outcome of patients with hepatocellular carcinoma

Beijing Ditan Hospital Affiliated to Capital Medical University

Research funding:

摘要

摘要:
越来越多的证据表明中性粒细胞与淋巴细胞比值(NLR)可作为炎症反应的评价指标,与多种恶性肿瘤的预后密切相关。归纳总结了NLR与肝细胞癌总生存期、无瘤生存期、肿瘤病理特征的关系及其主要作用机制的最新研究进展,认为NLR是评价肝细胞癌患者预后的方便、经济、有效的新指标。
- 癌,肝细胞 /
- 中性粒细胞与淋巴细胞比值 /
- 预后
Abstract:
Accumulating evidence has shown that neutrophil- lymphocyte ratio( NLR),as an assessment index for inflammatory response,is closely related to the prognosis of various malignant tumors. This article summarizes the research advances in the relationship of NLR with overall survival,disease- free survival,and pathological features of hepatocellular carcinoma and related mechanisms of action,and points out that NLR is a convenient,economic,and effective predictor for the prognosis of patients with hepatocellular carcinoma.
- carcinoma,hepatocellular /
- neutrophil-to-lymphocyte ratio /
- prognosis

HTML全文

参考文献(37)

[1]COUSSENS LM,WERB Z.Inflammation and cancer[J].Nature,2002,420(6917):860-867.

[2]GRIVENNIKOV SI,GRETEN FR,KARIN M.Immunity,inflammation,and cancer[J].Cell,2010,140(6):883-899.

[3]JAISWAL M,LARUSSO NF,BURGART LJ,et al.Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism[J].Cancer Res,2000,60(1):184-190.

[4]DAN J,ZHANG Y,PENG Z,et al.Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation[J].PLo S One,2013,8(3):e58184.

[5]YANG X,HUANG Y,FENG JF,et al.Prognostic significance of neutrophil-to-lymphocyte ratio in esophageal cancer:a meta-analysis[J].Onco Targets Ther,2015,21(8):789-794.

[6]ZHANG X,ZHANG W,FENG LJ.Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer:a meta-analysis[J].PLo S One,2014,9(11):e111906.

[7]LI MX,LIU XM,ZHANG XF,et al.Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer:a systematic review and meta-analysis[J].Int J Cancer,2014,134(10):2403-2413.

[8]YANG JJ,HU ZG,SHI WX,et al.Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer:a meta-analysis[J].World J Gastroenterol,2015,21(9):2807-2815.

[9]WEI Y,JIANG YZ,QIAN WH.Prognostic role of NLR in urinary cancers:a meta-analysis[J].PLo S One,2014,9(3):e92079.

[10]PENG B,WANG YH,LIU YM,et al.Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer:a systemic review and meta-analysis[J].Int J Clin Exp Med,2015,8(3):3098-3106.

[11]XIAO WK,CHEN D,LI SQ,et al.Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma:a meta-analysis[J].BMC Cancer,2014,14(1):1-10.

[12]LIMAYE AR,CLARK V,SOLDEVILA-PICO C,et al.Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma[J].Hepatol Res,2013,43(7):757-764.

[13]MOTOMURA T,SHIRABE K,MANO Y,et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol,2013,58(1):58-64.

[14]OKAMURA Y,ASHIDA R,ITO T,et al.Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma[J].World J Surg,2015,39(6):1501-1509.

[15]DAN J,ZHANG Y,PENG Z,et al.Postoperative neutrophil-tolymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation[J].PLo S One,2013,8(3):e58184.

[16]Mc NALLY ME,MARTINEZ A,KHABIRI H,et al.Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].Ann Surg Oncol,2013,20(3):923-928.

[17] PINATO DJ,SHARMA R.An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma[J].Transl Res,2012,160(2):146-152.

[18]GAO F,LI X,GENG M,et al.Pretreatment neutrophil-lymphocyte ratio:an independent predictor of survival in patients with hepatocellular carcinoma[J].Medicine(Baltimore),2015,94(11):e639.

[19]SUN XD,SHI XJ,CHEN YG,et al.Elevated preoperative neutrophil-lymphocyte ratio is associated with poor prognosis in hepatocellular carcinoma patients treated with liver transplantation:a meta-analysis[J].Gastroenterol Res Pract,2016,2016:4743808.

[20]LIAO W,ZHANG J,ZHU Q,et al.Preoperative neutrophil-tolymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection[J].Transl Oncol,2014,7(2):248-255.

[21]FU SJ,SHEN SL,LI SQ,et al.Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBVassociated hepatocellular carcinoma after radical hepatectomy[J].Med Oncol,2013,30(4):721.

[22]MANO Y,SHIRABE K,YAMASHITA Y,et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma:a retrospective analysis[J].Ann Surg,2013,258(2):301-305.

[23]CHEN TM,LIN CC,HUANG PT,et al.Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation[J].J Gastroenterol Hepatol,2012,27(3):553-561.

[24]TAIJIRI K,BABA H,KAWAI K,et al.Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection[J].J Gastroenterol Hepatol,2016.[Epub ahead of print]

[25]PINATO DJ,SHARAMA R.An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma[J].Transl Res,2012,160(2):146-152.

[26] CHEN TM,LIN CC,HUANG PT,et al.Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation[J].J Gastroenterol Hepatol,2012,27(3):553-561.

[27]POLLARD JW.Tumour-educated macrophages promote tumour progression and metastasis[J].Nat Rev Cancer,2004,4(1):71-78.

[28]KONO H,FUJII H,OGIKU M,et al.Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemia-reperfusion mice[J].J Immunol,2011,187(9):4818-4825.

[29]POON RT,FAN ST,LO CM,et al.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function:implications for a strategy of salvage transplantation[J].Ann Surg,2002,235(3):373-382.

[30]POON RT,FAN ST,LO CM,et al.Improving survival results after resection of hepatocellular carcinoma:a prospective study of 377 patients over 10 years[J].Ann Surg,2001,234(1):63-70.

[31]KUSUMANTO YH,DAM WA,HOSPERS GA,et al.Platelets and granulocytes,in particular the neutrophils,form important compartments for circulating vascular endothelial growth factor[J].Angiogenesis,2003,6(4):283-287.

[32]WU Y,ZHAO Q,PENG C,et al.Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop[J].J Pathol,2011,225(3):438-447.

[33]Mc DONALD B,SPICER J,GIANNAIS B,et al.Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms[J].Int J Cancer,2009,125(6):1298-1305.

[34]SCHREIBER RD,OLD LJ,SMYTH MJ.Cancer immunoediting:integrating immunity's roles in cancer suppression and promotion[J].Science,2011,331(6024):1565-1570.

[35]MULLER I,MUNDER M,KROPF P,et al.Polymorphonuclear neutrophils and T lymphocytes:strange bedfellows or brothers in arms?[J].Trends Immunol,2009,30(11):522-530.

[36]GU LL,LIU HM,ZHOU XB,et al.Efficacy of integrated traditional Chinese and Western medicine therapy based on vital qistrengthening,detoxicating,and qi stagnation-removing prescriptions in treatment of primary liver cancer[J].J Tradit Chin Med,2014,55(7):576-579.(in Chinese)谷莉莉,刘慧敏,周小兵,等.基于扶正解毒消积方的中西医结合方案治疗原发性肝癌的疗效分析[J].中医杂志,2014,55(7):576-579.

[37]LIU Y.Effect of vital qi-strengthening,detoxicating,and qi stagnation-removing prescriptions on 2-year survival rate and related mechanisms of action in patients with primary liver cancer[D].Beijing:Beijing Univ Chin Med,2015.(in Chinese)刘尧.扶正解毒消积方对原发性肝癌2年生存率的影响和作用机制研究[D].北京:北京中医药大学,2015.

施引文献

资源附件(0)

访问统计